Showing 6221-6230 of 6808 results for "".
- FDA Approves Keytruda for Advanced Melanomahttps://practicaldermatology.com/news/20140904-fda_approves_keytruda_for_advanced_melanoma/2459129/The FDA granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the
- Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirushttps://practicaldermatology.com/news/20140903-novan_to_present_antiviral_preclinical_results_of_nitric_oxide-releasing_drug_candidates_for_the_treatment_of_papillomavirus/2459131/Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, will present antiviral data from a preclinical animal study at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ta
- Advanced Dermatology and Cosmetic Surgery (ADCS Clinics) Announces the Acquisition of Fort Collins Skin Clinichttps://practicaldermatology.com/news/20140903-advanced_dermatology_and_cosmetic_surgery_adcs_clinics_announces_the_acquisition_of_fort_collins_skin_clinic/2459132/ADCS Clinics (“ADCS”) announced it has completed the acquisition of Fort Collins Skin Clinic in Fort Collins, Colorado; a dermatology practice owned by Dr. Brad Baack and Dr. Andy Kalajian (both Board Certified Dermatologist and fellowship trained Mohs Micrographic Surgeons). Baack and Kalajian, wit
- Promius Pharma, LLC: Finalist for PM360 Company of the Year Awardhttps://practicaldermatology.com/news/20140828-promius_pharma_llc_finalist_for_pm360_company_of_the_year_award/2459136/Promius Pharma, LLC has been named as a Trailblazer Company of the Year finalist by PM360, a publication that covers the pharmaceutical, biotech and medical device industries. Promius is one of three finalists in the category of Company of the Y
- Novan's Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugshttps://practicaldermatology.com/news/20140820-novans_nitricil_technology_shows_efficacy_against_multidrug_resistant_superbugs/2459140/Novan Therapeutics' Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe, according to new data. The
- Carma Laboratories Introduces New Carmex® Cold Sore Treatmenthttps://practicaldermatology.com/news/20140820-carma_laboratories_introduces_new_carmex_cold_sore_treatment/2459142/Carma Laboratories, Inc., the maker of Carmex® lip balm products, has launched the new Carmex® Cold Sore Treatment. This product features TriPLEX™ Formula advanced technology, which combines three different optical brightener and filler technologies that each provide unique appea
- Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, And Sinopharm A-Think Pharmaceutical Co., LTDhttps://practicaldermatology.com/news/20140818-provectus_signs_memorandum_of_understanding_with_sinopharm-china_state_institute_of_pharmaceutical_industry_and_sinopharm_a-think_pharmaceutical_co_lt/2459143/Negotiations on Licensing PV-10 in China Opened Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a Memorandum of Understanding (“MOU”) with
- Trevi Therapeutics Announces the Issuance of Two Patents for Oral Sustained Release Formulation of Nalbuphine ERhttps://practicaldermatology.com/news/20140815-trevi_therapeutics_announces_the_issuance_of_two_patents_for_oral_sustained_release_formulation_of_nalbuphine_er/2459144/Trevi Therapeutics, Inc. received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175. The Company believes that both of these patents will be Orange Book-li
- 'Sun Safe' Study: Children Seek Shade if Availablehttps://practicaldermatology.com/news/20140812-sun_safe_study_children_seek_shade_if_available/2459147/A new study by the founder of Sun Safe Soccer reveals nearly two-thirds of children will use shade tents during soccer breaks without any prompting from coaches. The study, published in JAMA Dermatology, was conducted by Ian Maher, M.D., who developed the Sun Safe Soccer skin cancer preve
- Editorial: Transferrable Loyalty and the State of Our Specialtyhttps://practicaldermatology.com/news/20140806-editorial_transferrable_loyalty_and_the_state_of_our_specialty/2459149/With the ongoing battle between Allergan and Valeant, it is evident that no practicing dermatologist can avoid concerns with the painful and tactical machinations. Long-term representatives have likely already changed their nametags from one company to another and are now pitching the same drugs und